Inter-individual differences in arsenic metabolism have been linked to arsenic-related disease risks. Arsenic (13) methyltransferase (AS3MT) is the primary enzyme involved in arsenic metabolism, and we previously demonstrated in vitro that N-6 adenine-specific DNA methyltransferase 1 (N6AMT1) also methylates the toxic inorganic arsenic (iAs) metabolite, monomethylarsonous acid (MMA), to the less toxic dimethylarsonic acid (DMA). Here, we evaluated whether AS3MT and N6AMT1 gene polymorphisms alter arsenic methylation and impact iAs-related cancer risks. We assessed AS3MT and N6AMT1 polymorphisms and urinary arsenic metabolites (%iAs, %MMA, %DMA) in 722 subjects from an arseniccancer case-control study in a uniquely exposed area in northern Chile. Polymorphisms were genotyped using a custom designed multiplex, ligationdependent probe amplification (MLPA) assay for 6 AS3MT SNPs and 14 tag SNPs in the N6AMT1 gene. We found several AS3MT polymorphisms associated with both urinary arsenic metabolite profiles and cancer risk. For example, compared to wildtypes, individuals carrying minor alleles in AS3MT rs3740393 had lower %MMA (mean difference 5 21.9%, 95% CI: 23.3, 20.4), higher %DMA (mean difference 5 4.0%, 95% CI: 1.5, 6.5), and lower odds ratios for bladder (OR 5 0.3; 95% CI: 0.1-0.6) and lung cancer (OR 5 0.6; 95% CI: 0.2-1.1). Evidence of interaction was also observed for both lung and bladder cancer between these polymorphisms and elevated historical arsenic exposures. Clear associations were not seen for N6AMT1. These results are the first to demonstrate a direct association between AS3MT polymorphisms and arsenic-related internal cancer risk. This research could help identify subpopulations that are particularly vulnerable to arsenic-related disease. 
Inter-individual differences in arsenic metabolism have been linked to arsenic-related disease risks. Arsenic (13) methyltransferase (AS3MT) is the primary enzyme involved in arsenic metabolism, and we previously demonstrated in vitro that N-6 adenine-specific DNA methyltransferase 1 (N6AMT1) also methylates the toxic inorganic arsenic (iAs) metabolite, monomethylarsonous acid (MMA), to the less toxic dimethylarsonic acid (DMA). Here, we evaluated whether AS3MT and N6AMT1 gene polymorphisms alter arsenic methylation and impact iAs-related cancer risks. We assessed AS3MT and N6AMT1 polymorphisms and urinary arsenic metabolites (%iAs, %MMA, %DMA) in 722 subjects from an arseniccancer case-control study in a uniquely exposed area in northern Chile. Polymorphisms were genotyped using a custom designed multiplex, ligationdependent probe amplification (MLPA) assay for 6 AS3MT SNPs and 14 tag SNPs in the N6AMT1 gene. We found several AS3MT polymorphisms associated with both urinary arsenic metabolite profiles and cancer risk. For example, compared to wildtypes, individuals carrying minor alleles in AS3MT rs3740393 had lower %MMA (mean difference 5 21.9%, 95% CI: 23.3, 20.4), higher %DMA (mean difference 5 4.0%, 95% CI: 1.5, 6.5), and lower odds ratios for bladder (OR 5 0.3; 95% CI: 0.1-0.6) and lung cancer (OR 5 0.6; 95% CI: 0.2-1.1). Evidence of interaction was also observed for both lung and bladder cancer between these polymorphisms and elevated historical arsenic exposures. Clear associations were not seen for N6AMT1. These results are the first to demonstrate a direct association between AS3MT polymorphisms and arsenic-related internal cancer risk. This research could help identify subpopulations that are particularly vulnerable to arsenic-related disease. Environ [Naujokas et al., 2013] . Chronic iAs ingestion is associated with increased risk of skin, lung, bladder, and kidney cancers, making iAs exposure a global health concern [Smith et al., 1992; Steinmaus et al., 2000] .
Humans metabolize ingested iAs through methylation pathways mainly in the liver [Gebel, 2002; Vahter, 2002; Tseng, 2007] . Once ingested, iAs undergoes oxidative methylation to monomethylarsonic acid (MMA V ) which is then reduced to monomethylarsonous acid (MMA III ). MMA III is methylated to dimethylarsinic acid (DMA V ) and a small amount is further reduced to dimethylarsinous acid (DMA III ) [Drobna et al., 2009b] . This metabolism process is incomplete in humans; therefore, all three forms (iAs, MMA, and DMA) are excreted in urine. Since MMA III is rather unstable, most epidemiology studies report total MMA (MMA III 1 MMA V ) present in urine [Kalman et al., 2013] . Traditionally, iAs methylation was considered a detoxification pathway; however in vitro evidence supports that MMA III is more toxic to human cells than iAs or any other metabolite [Petrick et al., 2000; St yblo et al., 2002] . In fact, a number of human studies have identified associations between increased MMA and decreased DMA percentages in urine and higher risk of skin, bladder and lung cancers and other arsenic related disease Smith and Steinmaus, 2009] . This suggests that individuals with less efficient arsenic metabolism may be particularly susceptible to arsenic toxicity.
There is considerable inter-individual variation in arsenic metabolism [Vahter, 1999] . The efficiency of arsenic metabolism is evaluated by the relative distribution of urinary arsenic metabolites [Buchet et al., 1981] . Average proportions of urinary iAs, MMA, and DMA across human population studies are 10-20%, 10-15%, and 60-75%, respectively [Hopenhaynrich et al., 1993] . Multiple factors contribute to inter-individual variability in urinary arsenic metabolites. For example, sex, age, smoking status, levels of exposure, and folate intake all affect the proportion of arsenic metabolites excreted in urine [Gamble et al., 2006; Kile et al., 2009] . Genetic polymorphism may also influence inter-individual variability [Vahter, 2000; Engstr€ om et al., 2007] . However, the factors that determine most of the variation in arsenic metabolism, and the factors that make some people more susceptible to arsenic related disease than others, remain mostly unexplained. Understanding the role of the factors that impact arsenic metabolism might help identify individuals who are particularly susceptible to arsenic toxicity.
The activity of enzymes involved in converting MMA III to DMA V may influence toxicity resulting from arsenic bioactivation. Arsenic (13 oxidation state) methyltransferase (AS3MT) is the primary enzyme involved in catalyzing arsenic methylation [Thomas et al., 2007] . However, As3mt knockout mice did not exhibit abolished arsenic metabolism, suggesting that alternative enzymes facilitate this methylation process [Drobna et al., 2009a] . Our previous in vitro study identified the novel role of N-6 adenine-specific DNA methyltransferase 1 (N6AMT1), a putative methyltransferase, in converting MMA III to DMA V [Ren et al., 2011] . A more recent in vitro investigation confirmed that N6AMT1 is involved in MMA III methylation, but its effects were secondary to AS3MT [Zhang et al., 2015] . Although several epidemiology studies have found associations between AS3MT polymorphisms and the proportion of MMA in urine [Engstr€ om et al., 2011 [Engstr€ om et al., , 2007 Pierce et al., 2012; Drobn a et al., 2016] , few have examined cancer risk in the same study population [Chung et al., 2009; Engstr€ om et al., 2015] , and only two have assessed the role of N6AMT1 polymorphisms in arsenic metabolism [Harari et al., 2013; Chen et al., 2017] .
We previously examined the association between arsenic methylation and cancer in an arsenic exposed population from Chile, and found higher lung and bladder cancer risks associated with increased %MMA in urine [Melak et al., 2014] . In this study, we extend these analyses to investigate the role of AS3MT and N6AMT1 polymorphisms in arsenic metabolism as well as internal cancer risk.
MATERIALS AND METHODS

Study Populations
The study uses data from participants that were recruited in northern Chile as part of a case-control study of arsenic and cancer. Details on subject recruitment and participation rates are described in Steinmaus et al. [2013] . Briefly, the study area comprised two contiguous regions (Regions I, II) in northern Chile. All incident cases of primary lung and bladder cancer newly diagnosed from October 2007 to December 2010 were ascertained from all pathologists, hospitals, and radiologists in the study area. Controls, frequency matched to cases by sex and five-year age groups, were randomly selected from computerized voter registration lists for Regions I and II, which include >95% of the population over age 50 in these regions. The appropriate review boards in the United States and Chile approved this study, and informed consent was obtained from all participants.
For this study, subjects had to be alive at the time of the interview and able to provide a urine sample and either blood or saliva for genotyping. Of the 937 living subjects in the original Chile case-control study, we genotyped 722 participants using 557 clots and 165 saliva samples that were collected during the study. We did not limit samples to matched pairs with genotyping information, thus the subset of study participants comprised different numbers of cases and controls. The response rate of participants did not differ between cases (75.1%) and controls (77.8%). Urinary arsenic metabolites were measured in the first 558 subjects recruited in the original case-control study, which included 494 of the genotyped subjects. The subset of individuals with genotype and metabolite data was comparable to the original case-control study population in terms of mean age, sex, smoking, and cancer status (Supporting Information Table I ).
Urine Sample Collection and Analysis
A single first morning urine sample was collected from subjects. A previous study found a correlation between arsenic excretion in single first morning samples and samples collected over 24 h [Calderon et al., 1999] . Urine samples were kept frozen in the field laboratories at 2208C and then transported on dry ice to the University of Washington, Seattle, for analysis. Urinary arsenic metabolites were measured using high performance liquid chromatography and inductively coupled mass spectrometry (HPLC-ICP/MS). Methodological details are provided elsewhere [Melak et al., 2014] All samples were stored frozen at 2808C for 1 to 4 months before analysis. The proportion of arsenic in each species in urine (%iAs, %MMA, and %DMA) was calculated by dividing the concentration of arsenic in each species by the sum of the concentrations of iAs, MMA, and DMA. Genomic DNA Purification and Quantification DNA was isolated from blood clots using the Gentra Puregene Blood Kit combined with Clotspin Baskets (Qiagen, Hilden, Germany) or saliva using Oragene TM saliva collection kits according to manufacturer's instructions (DNA Genotek Inc., Ontario, Canada). All DNA samples were quantified using PicoGreen dsDNA quantitation kits (Molecular Probes, Eugene, OR).
Genotyping AS3MT and N6AMT1Polymorphisms
We selected six AS3MT SNPs (rs7085104, rs3740400, rs3740393, rs3740390, rs11191439, rs1046778) based on previously reported associations with arsenic metabolism [Engstr€ om et al., 2011] . Except for rs11191439 (Met287Thr), all genotyped AS3MT SNPs were intronic polymorphisms. We aimed to survey all common genetic variants in the N6AMT1 gene to precisely map the association between SNPs and arsenic metabolism. All 108 polymorphisms in the gene region, including its 50 flanking region, with call rate >90% and minor allele frequency (MAF) 5% in Europeans (CEU) from the HapMap Project (release 28) were included. Fourteen tag SNPs were selected using Tagger within Haploview at r 2 > 0.8 [Barrett et al., 2005; de Bakker et al., 2005] and captured 100% of the common variability in N6AMT1. AS3MT and N6AMT1 polymorphisms were detected using a novel custom-designed assay based on the multiplex, ligation-dependent probe amplification (MLPA) method developed by MRC-Holland [Schouten et al., 2002] (www.mlpa.com). Protocol details are described in Akers et al. [2011] . Mixtures, concentrations, and sequences for each probe are provided in Supporting Information Table II. The PCR program was adapted to: 2 min at 988C; 32 cycles of 5 sec at 988C and 15 sec at 658C; 1 min 728C. Two probe pairs at non-variable sites were included in each reaction as positive controls for DNA quality. Blanks and control DNA samples were included on every plate for quality control. We verified our assay using 15 control DNA samples with known sequences acquired from the 1000 genomes project [The 1000 Genomes Project Consortium, 2012]. Additionally, we compared genotyping results for N6AMT1 tag SNP rs1048546 from our method against the TaqmanV R SNP genotyping assay (Applied Biosystems, Carlsbad, CA) using 150 randomly selected Chile samples. Agreement was 100% between both methods.
We performed linkage disequilibrium analysis and constructed haplotype blocks from the Chile genotyping data in Haploview using the solid spine method for AS3MT SNPs and the confidence intervals algorithm by Gabriel et al. [2002] for N6AMT SNPs (Fig. 1 ). Haplotypes were inferred by the PHASE software [Stephens and Donnelly, 2003] .
Statistical Analysis
Associations between genotypes or haplotypes and each urinary arsenic species (%MMA, %DMA and %InAs) were analyzed using multivariate linear regression. The genotype with the largest number of subjects was used as the reference genotype. Minor allele and haplotype frequencies <5% were declared as rare and combined. Genotypes/haplotypes were modeled as categorical variables (zero, one, or two minor allelles/ copies) and as zero copies versus at-least one minor allele or haplotype. Environmental and Molecular Mutagenesis. DOI 10.1002/em All metabolite models were adjusted for log transformed total urinary iAs concentrations, age (continuous), sex, current smoking status, and cancer case status.
Lung and bladder cancer odds ratios (ORs) were calculated for all SNPs and haplotypes using logistic regression. The relationship between genotypes/haplotypes, arsenic metabolism and cancer status were modeled in two ways: (1) Direct association between genotypes/haplotypes and cancer status; and, (2) Greater than additive biological interaction between historical arsenic water concentration exposures and genotypes/ haplotypes on cancer ORs. Both approaches were adjusted for age, sex, and current smoking status. Further adjustments for pack-years or average cigarettes smoked had little impact on results. To examine synergy, we stratified subjects by genotypes and by having ever smoked or by highest average contiguous 5-year arsenic water concentrations, excluding the 5-years prior to cancer diagnosis or subject interview, above and below 200 lg L 21 . This cut-off divides the subjects into two approximately equal sized exposure groups. Details on calculating the highest average contiguous 5-year arsenic water concentrations can be found in Steinmaus et al. [2013] . Analyses were performed with R software, version 3.1.3 [R Core Team, 2015] . The epiR package was used to calculate Rothman synergy indices [Stevenson et al., 2015] .
Mediation analyses were conducted to identify the indirect association between AS3MT genotypes and cancer risk attributed to differences in %MMA relative to the total association. We implemented the mediation package using nonparametric bootstrapping with 1000 iterations to quantify the proportion mediated and obtain 95% confidence intervals for these estimates [Tingley et al., 2014] .
RESULTS
Of the 937 living subjects in the original Chile casecontrol study, 119 lung cancer cases, 147 bladder cancer cases and 456 controls were genotyped for AS3MT and N6AMT1 SNPs. All polymorphisms were in Hardy-Weinberg equilibrium (P < 0.001) and had a MAF > 5%. Among the AS3MT SNPs, rs7085104 was in strong linkage disequilibrium (LD) with rs3740400 (R 2 5 0.95) and rs3740393 showed modest LD with rs3740390 (R 2 5 0.89) (Fig. 1) . The AS3MT minor allele frequencies in this population were similar to previously published studies from Mexico [Drobn a et al., 2016] , Bangladesh [Engstr€ om et al., 2011] , and Mongolia [Chen et al., 2017] (Fig. 2) . Table I lists the mean proportions of each arsenic species stratified by case status, sex, age, current smoking status, and race for the 494 individuals with genotype and metabolite information in the study. All of these variables, except for race, were significantly associated with at least one arsenic metabolite and were adjusted for in all regression analyses.
We found statistically significant associations between AS3MT SNPs-rs3740393, rs3740390, rs11191439, rs1046778-and urinary arsenic metabolites, even after adjusting for total urinary arsenic, age, sex, current smoking status, and case status (Table II) . There was a 3.0 (95% CI: 2.1, 4.0) percent increase in the proportion of MMA among carriers of the rs11191439 minor allele (Thr). A monotonic decrease in %MMA was also observed with each additional copy of the mutant allele for the other three SNPs. Associations between all AS3MT polymorphisms and %DMA were in the opposite direction and of similar magnitude compared to those associations identified with %MMA. These associations remained even after restricting the analysis to control subjects (Supporting Information Table III) .
Associations between AS3MT polymorphisms and %MMA were in the same direction as the bladder and lung cancer odds ratios (Table II) . For example, individuals carrying the rs11191439 minor allele (Thr), the polymorphism associated with the greatest increase in %MMA, had a statistically significant increase in lung cancer (OR 5 1.7; 95% CI: 1.0, 2.7) and a modest increase in bladder cancer (OR 5 1.3; 95% CI: 0.8, 2.1). Having at least one copy of the rs3740393 minor allele (C) was associated with both decreased lung and bladder cancer odds ratios (OR 5 0.6; 95% CI: 0.4, 0.9 and OR 5 0.5; 95% CI: 0.3, 0.8 for lung and bladder cancer, respectively). The minor alleles of AS3MT SNPs rs3740390 (A) and rs1046778 (C) were also associated with reduced bladder cancer odds ratios.
Mediation analysis revealed that 39.8% (P 5 0.02) of the association between AS3MT SNP rs11191439 and lung cancer could be attributed to differences in %MMA. We also found that 33.5% (P 5 0.04) of the association between rs3740393 and lung cancer was mediated by %MMA. The proportion of the association between AS3MT SNPs and bladder cancer mediated by %MMA was <5% and not statistically significant (data not shown).
Cancer ORs stratified by historical arsenic exposure and polymorphisms are shown in Table III . For rs11191439, compared to subjects with arsenic exposures <200 mg L 21 and genotype Met/Met, the lung cancer OR for exposures >200 mg L 21 was greater in those with at least one copy of the Thr allele (OR 5 5.6; 95%CI: 3.0, 10.7), compared to wild-type (OR 5 2.6; 95% CI: 1.6, 4.3; Rothman synergy index 5 3.6, 95% CI: 1.2, 11.1). Evidence of interaction was also seen between arsenic and having at least one copy of the rs3740393 minor allele (C) for both lung and bladder cancer, although with Rothman synergy indices below 1.0 (i.e., antagonism).
We also examined the interaction between AS3MT SNPs and smoking in lung and bladder cancer. The minor allele of AS3MT SNPs rs3740393, rs3740390, and rs1046778 were protective against lung cancer among individuals who reported ever smoking (Supporting Information Table IV ). Rothman synergy indices for each of these SNPs were 0.3 (95% CI: 0.1, 0.8), 0.3 (95% CI: 0.1, 0.8), and 0.4 (95% CI: 0.2, 0.9), respectively. Further adjustment for %MMA had little impact on these results (data not shown). There was no evidence of interaction between AS3MT SNPs and having ever smoked for bladder cancer (Supporting Information Table IV) .
Haplotypes were inferred from all six AS3MT polymorphisms (rs7085104, rs3740400, rs3740393, rs3740390, rs11191439, rs1046778) and analyzed in relation to urinary arsenic metabolites and cancer case status. The observed haplotypes were AAGGTT (51%), GCCATC Odds ratio (OR) compared to individuals homozygous for reference allele adjusted for age, sex and current smoking status.
*Statistically significant (P < 0.05) association.
Environmental and Molecular Mutagenesis. DOI 10.1002/em (25%), GCGGCT (11%), and GCGGTC (8%), with their frequencies listed in parentheses. The results from the haplotype analyses were similar to those obtained with individual SNPs (Supporting Information Table V) . We observed a monotonic decrease in both %MMA and the bladder cancer odds ratio with each additional copy of the GCCATC haplotype. Furthermore, there was a 3.0 (95% CI: 2.1, 4.0) percent increase in MMA and a lung cancer OR of 1.7 (95% CI: 1.0, 2.7) among individuals with one copy of the GCGGCT haplotype. Unlike AS3MT, there were no associations between N6AMT1 tag SNPs and urine arsenic metabolite proportions that corresponded to differences in cancer risk (Table IV) . For example, rs7282280 was the only tag SNP associated with a statistically significant decrease in %MMA and an increase in %DMA, but was not associated with cancer ORs. The haplotype analysis of N6AMT1 tag SNPs did not provide any additional information beyond the individual SNPs (data not shown).
DISCUSSION
This study provides strong evidence that multiple AS3MT polymorphisms impact arsenic metabolism capacity and lung and bladder cancer risks in a Chilean population exposed to arsenic in drinking water. We identified several AS3MT polymorphisms associated with lung and/or bladder cancer risks, and all of these were associated with arsenic metabolic patterns that were consistent with these risks. For example, in vitro research has shown that MMA is a highly toxic metabolite of ingested arsenic, and the polymorphisms we found linked to decreases in %MMA were also linked to decreases in cancer risk. This consistency not only supports our findings linking these polymorphism to cancer, they also support our hypothesis that MMA may be the primary arsenic species responsible for these effects.
We observed that the minor allele of AS3MT SNPsrs3740393 (C), rs3740390 (A), and rs1046778 (C)-were associated with decreased %MMA and increased %DMA, suggesting that carriers of these alleles metabolize arsenic more efficiently compared to the majority of individuals in our study who had the reference allele. The direction of these associations are consistent with those seen in other population studies [Chung et al., 2009; Agusa et al., 2009; Engstr€ om et al., 2011 Engstr€ om et al., , 2007 Drobn a et al., 2016] . We also confirmed previous findings that the Thr allele of rs111191439 increases %MMA and lowers %DMA [Lindberg et al., 2007; Hern andez et al., 2008; Agusa et al., 2009; Valenzuela et al., 2009; Engstr€ om et al., 2011] . A review of AS3MT SNPs highlights the global relationship between rs3740393 and rs11191439 with arsenic metabolism efficiency [Agusa et al., 2011] . In 2014, another review conducted a pooled analysis of all published studies and observed that rs3740390 and rs11191439 were associated with statistically significant changes in %MMA across multiple populations [Antonelli et al., 2014] . The reproducibility of these SNPs in our study confirms their importance in arsenic metabolism across several populations, including Chile.
To date, few studies have examined the relationship between AS3MT polymorphism and internal cancer risk. For instance, our study is the first to analyze the relationship between these polymorphisms and lung cancer. This is particularly important because lung cancer is the number one cause of long-term mortality from ingested arsenic [Smith et al., 2006; Marshall et al., 2007] . We demonstrate that a significant proportion of the association between AS3MT polymorphisms and lung cancer risk is mediated [Lesseur et al., 2012] . A similar case-control study in Southeastern Michigan did not find any direct associations between AS3MT SNPs rs7085104, rs3740400, rs11191439, or rs1046778 and bladder cancer. However, possessing at least one copy of the rs11191439 Thr allele, in addition to higher average arsenic exposure, did increase bladder cancer risk [BeebeDimmer et al., 2012] . We observed a similar result where individuals with historical arsenic exposure >200 mg L 21 and the rs11191439 Thr allele had a higher lung cancer OR compared to those with two copies of the wild-type allele, suggesting a gene-environment interaction. In both previous case-control studies, arsenic water concentrations were an order of magnitude lower than those in our study. This may have limited the ability of these studies to identify true associations, and highlights the potential advantage of investigating associations, at least initially, in areas where exposures are high. The reason we found evidence of greater mediation by %MMA for lung cancer than for bladder cancer is not entirely clear. Intra-individual variability in %MMA and the fact that we only assessed %MMA at a single point in time likely affected our mediation analysis although it is not clear that this would impact bladder cancer more than lung cancer. It is possible that inter-individual differences in %MMA have greater impacts on lung cancer. In a previous report using the same data we used here, associations with %MMA were seen for both cancer types but were two to three times greater for lung cancer. For each one percent increase in %MMA ORs were 1.11 (95% CI, 1.05-1.17) for lung cancer and 1.04 (95% CI, 1.00-1.09) for bladder cancer. It is also possible that other risk factors or other mechanisms have different roles in the two types of arsenic-related cancers but this is mostly speculative. Overall, further research is needed to explore this issue.
We did not observe clear associations between N6AMT tag SNPs, %MMA, and cancer risk. Harari et al. analyzed the N6AMT1 SNP rs1048546 in the San Antonio de los Cobres (SAC) population of highly arsenic-exposed indigenous women and observed a significant association with %MMA. In our analysis, the association between rs1048546 genotypes and %MMA was in the same direction observed by Harari et al., despite not being statistically significant. We confirmed that our null findings were not a result of the genotyping method. The reason for this inconsistency is unclear, but our population was much larger than the SAC population, had much lower recent arsenic exposure, and consisted of mostly males, smokers and Europeans. Several studies have shown marked differences in arsenic methylation patterns and genotypes based on ethnicity, and it is possible these caused the differences we identified [Engstr€ om et al., 2010; Fu et al., 2014] . Furthermore, the distribution of the protective AS3MT haplotype in the SAC population is higher than most populations around the world, making them extremely efficient arsenic metabolizers [Schlebusch et al., 2013 [Schlebusch et al., , 2015 . Therefore, the contribution of N6AMT1 to arsenic metabolism within this population may differ from Chile. Chen et al. also examined the relationship between several N6AMT tag SNPs included in our study and urinary metabolite patterns in an arsenic-exposed population from Wuyuan, Inner Mongolia [Chen et al., 2017] . Rs1003671 was the only N6AMT polymorphism associated with %MMA in the Mongolian population. This SNP did not influence arsenic metabolism or cancer risk in our study population. It is important to note that Chen et al. did not find a direct association between AS3MT polymorphisms and urinary metabolites, but did show interaction with between AS3MT and N6AMT1 SNPs on arsenic metabolism. This indicates that the involvement of these two enzymes in the arsenic metabolism process may differ between the Chilean and Mongolian populations. Overall, the inconsistency we observed for N6AMT1 limits any conclusions we can make regarding this gene at this time and suggest additional research may be needed on this topic. Furthermore, although the selected 14 tag SNPs capture all the common genetic variation in N6AMT in HapMap-CEU (r28), these might not cover the whole N6AMT variant spectrum in Chileans due to its admix ancestry nature. Therefore, additional tag SNPs selected from appropriate reference panels that better capture the LD structure in Chilean populations should be included in future analyses to get a better understanding of the association between N6AMT SNPs with %MMA and cancer risk in this population.
For this analysis, we only considered the influence of two methyltransferases on arsenic metabolism and toxicity. However, additional methyltranserases (e.g., DNMT1a and DNMT3b) and other enyzymes involved in one-carbon metabolism and glutathione biosynthesis, such as methylenetetrahydrofolate reductase (MTHFR), cystathionine-betasynthase (CBS), and glutathione-S-transferase omega 1 (GSTO1), have been shown to influence the metabolism process [Schl€ awicke Engstr€ om et al., 2009; Porter et al., 2010; Steinmaus et al., 2010; Engstr€ om et al., 2011] . Follow-up studies in this population should explore the contribution of these genes to the inter-individual variability in methylation patterns, as well as internal cancer risk.
Urinary methylation patterns were assessed after disease diagnosis and were assumed to be representative of subject's past methylation patterns. It is possible that using a cross-sectional urine collection at the time of cancer diagnosis influenced methylation status, either from the disease itself or through treatment and lifestyle changes adopted after diagnosis. However, we observed associations between genotypes and metabolites even after cancer cases were excluded. Studies assessing methylation patterns in the same individual over time suggests that patterns remain Environmental and Molecular Mutagenesis. DOI 10.1002/em fairly stable [Concha et al., 2002; Steinmaus et al., 2005] . Evidence also suggests that stable genetic factors play a more important role in determining inter-individual differences in methylation patterns than do factors that are likely to have greater day to day variability such as diet or smoking [Chung et al., 2002] . It should also be noted that although intra-individual variability in methylation patterns could lead to misclassification of past methylation patterns, because we collected and analyzed metabolites from all subjects using the same protocols, the resulting bias would most likely be non-differential and towards the null, not towards the positive associations identified.
Confounding is possible, however ORs did not change with further adjustments for potential confounders such as age, sex smoking, race, and body mass index. Some selection bias may have occurred as a result of only genotyping a portion of the total Chilean population and measuring urinary metabolites in a smaller subset of these individuals. However, the age, sex and smoking status distributions within these three groups were comparable suggesting that our results are still representative of the entire study population.
In conclusion, our results highlight the involvement of AS3MT in arsenic metabolism in humans, and identify polymorphisms in this gene that account for some interindividual variability of the metabolic process. Our study is the first to use the same population to provide evidence that AS3MT polymorphisms increase the risk of arsenicinduced lung and bladder cancers by reducing the metabolism of MMA to the less toxic DMA. This research may help identify subpopulations that are particularly susceptible to arsenic-induced lung and bladder cancer and who may need enhanced regulatory protection.
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